Healthcare Industry News: Inflammatory Bowel Disease
News Release - April 15, 2009
Resolvyx Appoints Industry Leader Philip Vickers as Chief Scientific OfficerBEDFORD, Mass.--(HSMN NewsFeed)--Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that it has appointed Philip J. Vickers, Ph.D., to the position of Chief Scientific Officer. In this role, Dr. Vickers will play a critical role in leading Resolvyx’s research and drug discovery activities, and will serve on the company’s management team. Dr. Vickers will also join the Resolvyx board of directors.
Before joining Resolvyx, Dr. Vickers was Senior Vice President and Head of US Research for Boehringer-Ingelheim and led the organization’s focus on developing small molecules and biotherapeutics for the treatment of immunological, inflammatory and cardiovascular disease.
Prior to Boehringer-Ingelheim, Dr. Vickers served as Vice President for Pfizer Global Research and Development and head of the Pfizer Research Technology Center in Cambridge, MA. He previously held various leadership positions within Pfizer’s R&D organization including Executive Director of Genomic and Proteomic Sciences, and he served on the Pfizer Discovery Technology Board and the Pfizer Research Leadership Team. Dr. Vickers has also worked at Merck Research Laboratories where his group conducted fundamental research on 5- lipoxygenase and cyclooxygenase-2 enzymes, resulting in the development of novel anti-inflammatory compounds. Dr. Vickers holds a Ph.D. in Biochemistry from the University of Toronto and a Bachelor of Science degree in Applied Biochemistry from the University of Salford, Manchester, England.
“Resolvyx is developing a novel class of potent lipid mediators derived from omega-3 fatty acids that have the potential to treat a broad range of inflammatory diseases, including asthma, Inflammatory Bowel Disease, arthritis, and ophthalmic indications such as dry eye and age-related macular degeneration,” said Philip Vickers, Ph.D. “I am excited to join the company and help guide R&D programs to provide further insights into the important biological activities of these mediators, and to translate extremely promising laboratory findings into a robust pipeline of products that become breakthrough medicines.”
“We are delighted that Phil is joining Resolvyx at such an exciting time, as we complete a Phase II trial in dry eye patients with RX-10045, our topical ophthalmology drug candidate, and enter Phase 1 with our oral drug candidate, RX-10001,” said Paul Rubin, Chief Executive Officer of Resolvyx. “Phil brings more than two decades of experience leading drug discovery for world-class R&D operations, and his depth of knowledge will be highly valued as our team continues to advance our therapeutic programs”.
Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. In particular, resolvins act to protect healthy tissue during an immuno-inflammatory response to infection, injury or other environmental challenge, and then act to resolve inflammation and promote healing after the insult has passed. Resolvins are shown to be highly potent and efficacious in pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, Inflammatory Bowel Disease, dry eye and retinal disease, among others.
Resolvins are potential drug candidates to treat a broad range of acute and chronic diseases caused by a failure to resolve the inflammatory response and restore immune homeostasis. Such diseases include auto-immune diseases (like Crohn’s disease, psoriasis and rheumatoid arthritis), allergic diseases (like asthma) and chronic inflammatory diseases (like atherosclerosis, degenerative retinal diseases, chronic dry eye and Alzheimer’s disease). Resolvins offer an entirely novel biological approach to treating significant inflammatory diseases, with a decreased potential for immuno-suppression.
About Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Resolvyx's drug R&D programs are focused on characterizing and developing resolvin-based compounds. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive portfolio of more than 55 patents and applications.
The company's headquarters are in Bedford, Massachusetts. For additional information, please visit http://www.resolvyx.com
Source: Resolvyx Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.